- Silodosin (Rapaflo) prevents unintended pregnancies in women who are the partners of men using it as an on-demand oral contraceptive.
Why this matters
- This study is the first to assess silodosin, an approved treatment for benign prostatic hyperplasia (BPH), as an on-demand, reversible, nonhormonal, nonbarrier method of contraception for men, say researchers.
- Researchers studied healthy, sexually active men in stable sexual relationships with fertile female partners (N=63) not using other contraceptive methods.
- They randomly assigned patients to receive either silodosin 8 mg or placebo 3 hours before masturbation for 30 days, analyzing postmasturbation semen and postejaculation urine for spermatozoa.
- Then, for 1 year, they provided all patients silodosin 8 mg for use 3 hours before vaginal intercourse.
- Funding: None disclosed.
- During the first part of the study, men receiving silodosin had no spermatozoa in either postmasturbation semen or postejaculation urine.
- During the second part, no men or their partners reported unintended pregnancies.
- This was a pilot study with a small sample size.
- Changes in semen volume might have made patients aware of switching from placebo to silodosin despite blinding.